Quantbot Technologies LP Takes $49,000 Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Quantbot Technologies LP bought a new position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 2,542 shares of the company’s stock, valued at approximately $49,000.

Other institutional investors have also added to or reduced their stakes in the company. FMR LLC boosted its holdings in shares of Syndax Pharmaceuticals by 33.6% in the 3rd quarter. FMR LLC now owns 49,248 shares of the company’s stock worth $948,000 after purchasing an additional 12,377 shares in the last quarter. Algert Global LLC lifted its position in Syndax Pharmaceuticals by 9.9% in the 3rd quarter. Algert Global LLC now owns 474,998 shares of the company’s stock worth $9,144,000 after buying an additional 42,870 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Syndax Pharmaceuticals by 6.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 695,947 shares of the company’s stock worth $13,397,000 after buying an additional 41,458 shares in the last quarter. Intech Investment Management LLC bought a new position in Syndax Pharmaceuticals during the third quarter valued at approximately $429,000. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. purchased a new position in shares of Syndax Pharmaceuticals during the third quarter worth approximately $15,165,000.

Syndax Pharmaceuticals Trading Up 1.3 %

Shares of Syndax Pharmaceuticals stock opened at $17.01 on Friday. Syndax Pharmaceuticals, Inc. has a 12-month low of $15.00 and a 12-month high of $25.34. The company has a market cap of $1.45 billion, a P/E ratio of -4.69 and a beta of 0.86. The company’s fifty day simple moving average is $18.29 and its two-hundred day simple moving average is $19.66.

Syndax Pharmaceuticals (NASDAQ:SNDX) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($0.98) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.13) by $0.15. The company had revenue of $12.50 million during the quarter, compared to the consensus estimate of $9.16 million. During the same period in the previous year, the company earned ($0.73) earnings per share. Analysts predict that Syndax Pharmaceuticals, Inc. will post -2.39 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms recently commented on SNDX. JPMorgan Chase & Co. increased their target price on shares of Syndax Pharmaceuticals from $33.00 to $38.00 and gave the company an “overweight” rating in a report on Thursday, November 21st. Stifel Nicolaus lifted their price objective on Syndax Pharmaceuticals from $40.00 to $41.00 and gave the stock a “buy” rating in a report on Monday, October 14th. UBS Group started coverage on Syndax Pharmaceuticals in a research note on Thursday, October 24th. They issued a “buy” rating and a $37.00 target price for the company. Barclays lifted their price target on Syndax Pharmaceuticals from $32.00 to $33.00 and gave the stock an “overweight” rating in a research note on Thursday, August 15th. Finally, Citigroup increased their price objective on Syndax Pharmaceuticals from $37.00 to $45.00 and gave the company a “buy” rating in a research note on Tuesday, November 19th. One analyst has rated the stock with a sell rating, one has issued a hold rating and ten have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $37.64.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).